| Dr Mark Anthony Vergara-gomez, MD | |
|
Ave. 65th Infanteria Km 8.3 Carr. 3, Hospital Upr, Dr. Federico Trilla, Carolina, PR 00984 | |
| (787) 757-1800 | |
| Not Available |
| Full Name | Dr Mark Anthony Vergara-gomez |
|---|---|
| Gender | Male |
| Speciality | Pulmonary Disease |
| Experience | 20 Years |
| Location | Ave. 65th Infanteria Km 8.3 Carr. 3, Carolina, Puerto Rico |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1619179058 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Hospital Upr, Dr Federico Trilla | Carolina, PR | Hospital |
| Entity Name | Recinto De Ciencias Medicas |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1255419859 PECOS PAC ID: 3678469962 Enrollment ID: O20040330000339 |
News Archive
Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia.
Chindex International, Inc., a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that it has entered into a contract to supply EUR5 million in laboratory and hospital products to Centers for Disease Control in China's Qinghai Province.
The International Rett Syndrome Foundation (IRSF) announces today ten (10) new research grants at leading global research institutions; a new Translational Research Program; and additional funding for current human clinical trials.
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
› Verified 9 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Mark Anthony Vergara-gomez, MD Pmb 285 Po Box 1283, San Lorenzo, PR 00754-1283 Ph: (787) 225-3452 | Dr Mark Anthony Vergara-gomez, MD Ave. 65th Infanteria Km 8.3 Carr. 3, Hospital Upr, Dr. Federico Trilla, Carolina, PR 00984 Ph: (787) 757-1800 |
News Archive
Microbiologist Karl Klose, a professor in the UTSA College of Sciences' Department of Biology and a member of the South Texas Center for Emerging Infectious Diseases, has received a contract from the U.S. Department of Defense (DOD) to conduct research that would bring scholars one step closer to developing a vaccine against tularemia.
Chindex International, Inc., a leading independent American provider of Western healthcare products and services in the People's Republic of China, today announced that it has entered into a contract to supply EUR5 million in laboratory and hospital products to Centers for Disease Control in China's Qinghai Province.
The International Rett Syndrome Foundation (IRSF) announces today ten (10) new research grants at leading global research institutions; a new Translational Research Program; and additional funding for current human clinical trials.
Ambit Biosciences, a biopharmaceutical company focused on discovery and development of drugs targeting unmet needs in oncology, autoimmune and inflammatory disease, today announced the initiation of the Phase 2 cohort of the MD Anderson Cancer Center-sponsored Phase 1/2 study of quizartinib in combination with either 5-azacitidine or low dose cytarabine for previously untreated FLT3-ITD positive acute myeloid leukemia (AML) patients age 60 or older, or FLT3-ITD positive AML patients 18 years of age or older in first relapse.
› Verified 9 days ago
Dr. Luis R Lopez-ruyol, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 117 A #4 Roberto Clemente Ave, Urb Villa Carolina, Carolina, PR 00985 Phone: 787-762-0700 Fax: 787-762-0700 | |
Dr. Anisonia Martinez Hernandez, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Ave Iturregui, Country Club, Carolina, PR 00985 Phone: 787-768-4278 | |
Dr. Teresa Monge, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: Qk25 Calle 533, 4th Ext. Country Club, Carolina, PR 00982 Phone: 787-276-4688 | |
Victor Manuel Arroyo, MD Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: Cond Plaza Altantico, Apt 1402, Carolina, PR 00979 Phone: 787-380-2439 | |
Dr. Hector Santos, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: Escorial Building One 1400 Avenue Sur Suite160, Carolina, PR 00987 Phone: 787-257-1511 Fax: 787-257-1881 | |
Vanessa Velazquez, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: Go4-b Campo Rico Avenue, Country Club, Carolina, PR 00982 Phone: 787-750-0444 Fax: 787-750-0195 | |
Dr. Monica Cespedes Santana, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4735 Ave Isla Verde Apt 5k, Carolina, PR 00979 Phone: 787-342-2784 |